Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Two-part, Dose-ranging, Adaptive Study to Evaluate Efficacy and Safety of THRV-1268 in Participants Diagnosed With Long QT Syndrome Type 2 (LQTS 2) and Type 3 (LQTS 3)

NCT07277582 is registered in ClinicalTrials.gov with Thryv Therapeutics, Inc. as lead sponsor.

NCT NCT07277582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07277582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Two-part, Dose-ranging, Adaptive Study to Evaluate Efficacy and Safety of THRV-1268 in Participants Diagnosed With Long QT Syndrome Type 2 (LQTS 2) and Type 3 (LQTS 3)
Lead sponsor
Thryv Therapeutics, Inc.
Phase
Phase 2/3
Overall status
Recruiting
Start date
March 7, 2026
Completion date
June 30, 2027
Enrollment
84 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

long qt syndrome (lqts) 2